Pharmaceutical - Pharmaceutical, North America, Politics


1 to 25 of 44 results

Potential growth trajectories for the US biopharmaceutical sector

Potential growth trajectories for the US biopharmaceutical sector


The Pharmaceutical Research and Manufacturers of America (PhRMA) yesterday released a report that outlines…

North AmericaPharmaceuticalPoliticsResearchUSA

Patent lawyer seeking US Senate seat proposes patent reform to lower Rx drug costs


Republican Art Gardner, a patent attorney seeking election to the US Senate in Georgia, has issued a…

North AmericaPatentsPharmaceuticalPoliticsPricingUSA

US CMS withdraws contentious Medicare Part D proposals


The US Centers for Medicare & Medicaid Services (CMS) has halted movement on several proposals in its…

HealthcareNorth AmericaPharmaceuticalPoliticsUSA

PhRMA slams US President’s claims that Budget invests in innovation


Pharmaceutical Research and Manufacturers of America (PhRMA) president and chief executive John Castellani…

GenericsNorth AmericaPatentsPharmaceuticalPoliticsResearchUSA

PhRMA opposes proposed rule on US Medicare Advantage & Part D

PhRMA opposes proposed rule on US Medicare Advantage & Part D


Pharmaceutical Research and Manufacturers of America (PhRMA) stated yesterday that it is opposed to the…

North AmericaPharmaceuticalPoliticsUSA

Report shows weak US oversight of drug discount program for the uninsured

Report shows weak US oversight of drug discount program for the uninsured


A group of Republican Senate and House lawmakers in the USA released statements in response to a report…

North AmericaPharmaceuticalPoliticsUSA

Record $122 million increase for Alzheimer's disease passed by US Congress


An unprecedented $122 million increase for Alzheimer's research, education, outreach and caregiver support…

FinancialHealthcareNeurologicalNorth AmericaPharmaceuticalPoliticsResearchUSA

Canadian government concludes CETA, which is welcomed by Rx&D


Canada’s Research-Based Pharmaceutical Companies (Rx&D) association applauds the government of Canada’s…

EuropeNorth AmericaPatentsPharmaceuticalPoliticsResearch

Canada welcomes Comprehensive Economic and Trade Agreement with Europe


Canada’s Research-Based Pharmaceutical Companies (Rx&D) group has welcomed the Canadian Government’s…

EuropeNorth AmericaPharmaceuticalPolitics

Update on US FDA activities in ongoing govt shutdown


We are now entering the second week of the shutdown of the US federal government (or “the lapse period”…

North AmericaPharmaceuticalPoliticsRegulation

Impact of partial government shutdown on US FDA


According to contingency plans drawn up by the USA’s Department of Health and Human Services, 45% of…

North AmericaPharmaceuticalPoliticsRegulation

US Senator seeks answers from drugmakers on providing required discounts


US Senator Charles Grassley has written to two drug companies on behalf of an Iowa hospital that is not…

CSL BehringExparelHematologyKcentraNeurologicalNorth AmericaPacira PharmaceuticalsPharmaceuticalPoliticsPricing

Pharma associations strongly support Senate bill on FDA User Fees sequestration exemptions


In the USA last week, Mark Pryor (Democrat, Arkansas), chairman of the Senate Appropriations Subcommittee…

BiotechnologyFinancialGenericsLegalNorth AmericaPharmaceuticalPolitics

HAI Europe questions pharma commitment to clinical trial data transparency, claiming leaked documents suggest otherwise


Consumer advocacy Health Action International (HAI) Europe says it welcomes any initiative that grants…

BiotechnologyEuropeNorth AmericaPharmaceuticalPoliticsRegulationResearch

Bipartisan Bill exempting FDA user fees from sequestration introduced in USA


A bipartisan group of US House of Representatives Members last week introduced the FDA Safety Over Sequestration…

BiotechnologyFinancialLegalNorth AmericaPharmaceuticalPolitics

Drug discount program sparks more debate between hospitals and critics in the USA


Debate in the USA has flared again over how hospitals are using a discount prescription drug program.

HealthcareNorth AmericaPharmaceuticalPolitics

Canadians have access to fewer new medicines than in most OECD countries


Compared to 32 other developed countries, Canada's public drug plans perform poorly in providing access…

HealthcareNorth AmericaPharmaceuticalPoliticsRegulation

Tightening health budgets on both sides of the Atlantic leading to crackdowns on patent settlements, says EIU analyst


Later this month, following an inquiry launched in 2009, the European Commission is expected to impose…

EuropeFinancialGenericsNorth AmericaPatentsPharmaceuticalPoliticsRegulation

US Senator Grassley questions continue about 340B discount drug program


US Senator Chuck Grassley (Republican, Iowa) is looking into how hospitals are using a discount prescription…

North AmericaPharmaceuticalPoliticsPricing

USTR releases "Special 301" report that disappoints PhRMA


The Office of the United States Trade Representative (USTR) has released its annual "Special 301" Report…

GlobalNorth AmericaPatentsPharmaceuticalPolitics

President Obama's 2014 budget proposal a mixed bag for pharma


US President Barack Obama $3.77 trillion budget proposal for fiscal 2014 delivers mixed news for the…

BiotechnologyFinancialHealthcareNorth AmericaPharmaceuticalPolitics

US Senator calls for re-examination of pricing of drugs developed with public funds


US Senator Ron Wyden (Democrat, Oregon) has released a letter written to National Institutes of Health…

North AmericaPfizerPharmaceuticalPoliticsPricingResearchXeljanz

Mixed views from PhRMA and GPhA on Obama's State of the Union Address


There were mixed reactions from two sides of the US drug industry - research-based and generic drugmakers…

FinancialGenericsHealthcareNorth AmericaPharmaceuticalPolitics

Canadian Senate committee finds faults in current clinical trials system


The absence of a standardized approach to research ethics review significantly impacts the time required…

BiotechnologyNorth AmericaPharmaceuticalPoliticsRegulationResearch

1 to 25 of 44 results

Back to top